Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zelboraf

Roche - Basel

Roche’s blood cancer antibody wins priority review in US

Obinutuzumab is fast-tracked by FDA in treatment of chronic lymphocytic leukaemia

- PMLiVE

Roche pays $220m for blood-testing company

Boosts diagnostics business with acquisition of Constitution Medical Investors

- PMLiVE

UK relaunches lung cancer campaign

Follows success in previous awareness push

- PMLiVE

Roche’s Perjeta on US fast-track for early breast cancer

FDA grants priority review for drug's use before surgery

- PMLiVE

Roche and AstraZeneca to share early trial data

Unique big pharma collaboration aims to increase their R&D efficiency

- PMLiVE

Roche’s Avastin gains Japanese approval for brain cancer

Marks drug's first approval to treat newly diagnosed glioblastoma

- PMLiVE

NICE knocks back Lilly’s Alimta in new setting

Institute not recommending Lilly’s lung cancer drug for new licence extension

Roche - Basel

EU approves new use of Roche’s RoActemra in children

Swiss pharma firm hopes to increase revenue from arthritis drug to tip it into blockbuster status

- PMLiVE

ASCO: Boehringer’s nintedanib boosts survival in lung cancer subset

Trial date demonstrates benefit in NSCLC patients with adenocarcinomas

- PMLiVE

Roche is drawn to science for YouTube campaign

Therapeutic antibodies, stem cells and Zebrafish tackled in series of fun videos

- PMLiVE

US FDA approves Roche’s assay as first blood test to diagnose diabetes

Will help catch diabetes early in country where seven million people are undiagnosed

- PMLiVE

Roche repeats cancer drugs warning as Avastin faces another NICE rejection

Concerns about future of Cancer Drugs Fund

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links